MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Sponsor
Pfizer
Study ID
NCT04798586
Phase
PHASE1
Status
Completed

Conditions

  • Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to confirm the safety and tolerability of elranatamab (PF-06863135) in Japanese participants with relapsed or refractory MM.

Key Dates

First listed
Mar 15, 2021
Start date
Mar 22, 2021
Status verified
May 2024
Primary completion
May 27, 2022
Completion
May 17, 2023

Study Design

Enrollment
4 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Elranatamab (PF-06863135)
    BCMA-CD3 bispecific antibody

Primary Outcome Measure

Number of Participants With Dose Limiting Toxicities (DLTs) [ Time Frame: Up to 4 weeks ]

Related Studies